TOP2A and β-tubulin transcript levels predict response to anthracycline or taxane containing chemotherapy, respectively. A) ROC analysis of TOP2A transcript levels and response to TFAC neoadjuvant chemotherapy (AUC: 0.61, p = 0.008). B) Expression levels of TOP2A transcripts in patients who experienced pCR or had RD after neoadjuvant chemotherapy ( p = 0.04, t-test). C) ROC analysis of β-tubulin transcript levels and response to neoadjuvant docetaxel chemotherapy (AUC: 0.9, p = 0.001). D) Expression levels of β-tubulin transcripts in patients who experienced pCR or had RD after neoadjuvant docetaxel chemotherapy ( p < 0.0001, t-test).